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ABSTRACT
FGF applied as a single growth factor to quiescent mousefibroblasts induces a round of DNA replication, however continuous stimulation results
in arrest in the G1 phase of the next cell cycle. We hypothesized that FGF stimulation induces the establishment of cell memory, which prevents
the proliferative response to repeated or continuous FGF application. When a 2–5 days quiescence period was introduced between primary and
repeated FGF treatments, fibroblasts failed to efficiently replicate in response to secondary FGF application. The establishment of “FGFmemory”
during the first FGF stimulation did not require DNA synthesis, but was dependent on the activity of FGF receptors, MEK, p38 MAPK and NFkB
signaling, and protein synthesis. While secondary stimulation resulted in strongly decreased replication rate, we did not observe any attenuation
ofmorphological changes, Erk1/2 phosphorylation and cyclin D1 induction. However, secondary FGF stimulation failed to induce the expression
of cyclin A, which is critical for the progression fromG1 to S phase. Treatment of cells with a broad range histone deacetylase inhibitor during the
primary FGF stimulation rescued the proliferative response to the secondary FGF treatment suggesting that the establishment of “FGF memory”
may be based on epigenetic changes. We suggest that “FGF memory” can prevent the hyperplastic response to cell damage and inflammation,
which are associated with an enhanced FGF production and secretion. “FGF memory”may present a natural obstacle to the efficient application
of recombinant FGFs for the treatment of ulcers, ischemias, and wounds. J. Cell. Biochem. 115: 874–888, 2014.  2013 Wiley Periodicals, Inc.
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Fibroblast growth factors (FGF), which signal through specificFGF receptors (FGFR) 1–4, induce DNA synthesis in quiescent
cells, stimulate cell migration, and cause a drastic change of cellular
morphology, including cell polarization and reorganization of the
actin cytoskeleton [Friesel and Maciag, 1999]. Despite strong
immediate effects of FGFs in vitro, attempts to use them for tissue
repair have been marginally successful thus far [Barrientos
et al., 2008]. The application of recombinant FGF1 and FGF2 released
from implanted gels either moderately stimulated wound healing
[Kawaguchi et al., 2010] or had no significant effect [Kusuhara
et al., 2011]. We found that long‐term FGF1 stimulation of mouse
fibroblasts in culture resulted in an initial wave of DNA replication
and mitoses, which was followed by cell blockage in the G1 phase of
the next cell cycle [Andreeva et al., 2004] despite the continuous
activation of FGFR1 and Erk1/2.
We hypothesized that as a result of a single FGF stimulation the cell
loses the ability of proliferative response to the repeated application
of FGF. This phenomenon could repress the hyperplastic response to
tissue damage or inflammation, which are associated with the release
of ubiquitously expressed FGF1 and FGF2 [Khurana et al., 2004;
Ribeiro et al., 2012]. It could also explain why recombinant FGF often
only modestly affects wound healing. In the present study, we found
that Swiss 3T3 fibroblasts and several other types of cells maintain
“memory” about FGF for several days after the initial stimulation, and
as a result respond to the repeated FGF stimulation with drastically
reduced proliferation. The establishment of “FGF memory” does not
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depend on DNA synthesis during the first round of stimulation and
requires the activation of MEK and p38 MAPK as well as NFkB
signaling and histone deacetylase activity.
MATERIALS AND METHODS
CELL CULTURES
Swiss 3T3 (ATCC, Manassas, VA) cells were maintained in DMEM
(HyClone, Logan, UT) supplemented with 10% bovine calf serum
(HyClone) and 1% antibiotic/antimycotic mixture (GIBCO, Grand
Island, NY). Quiescence was induced by culturing cells in DMEM
containing 0.2% bovine calf serum and 5 units/ml heparin (Sigma, St.
Louis, MO). Similar cell culture conditions were used for 10T1/2
mouse mesenchymal stem cells (ATCC). LEII immortalized mouse
lung endothelial cells [Friesel and Maciag, 1988], mouse ear‐derived
mesenchymal stem cells (gift of Robert Koza, MMCRI), and human
adipose‐derived stem cells (gift of Thomas Tulenko, Rowan
University) were maintained in DMEM supplemented with 10% fetal
calf serum (HyClone). Quiescence was induced via serum starving in
DMEM containing 0.2% fetal calf serum and 5 units/ml heparin. For
spontaneous transformation, Swiss 3T3 cells were cultivated in the
medium with 10% fetal calf serum (HyClone) and left after achieving
100% confluency for a week without replating. This procedure was
repeated 10 times, at this point cultures were overgrown with
spontaneously transformed cells unable to reach quiescence neither
at high cell density nor in low serum.
CELL STIMULATION WITH GROWTH FACTORS AND TREATMENT
WITH INHIBITORS
Stimulation schedules for the standard repeated FGF1 stimulation
experiment were as follows:
 Q: 168 h of quiescence
 QF: 132 h of quiescence followed by 36 h FGF1 stimulation in the
absence of other growth factors
 QFQQ: 48 h quiescence, 36 h FGF1 stimulation, and 84 h of
additional quiescence
 QFQF: 48 h quiescence, 36 h FGF1 stimulation, 48 h of intermediate
quiescence followed by 36 h of repeated FGF1 stimulation
In a variation of the repeated stimulation experiment, the
intervening quiescence period between FGF1 stimulations was
extended from 48 to 120 h. In all experiments, we used recombinant
human FGF1 prepared as described [Forough et al., 1991] at 10 ng/ml
in DMEM with 5 U/ml heparin and 0.2% bovine calf serum. The same
four basic stimulation schedule conditions were followed in repeated
stimulation experiments for other polypeptide growth factors: FGF2,
PDGF‐BB (both from R&D Systems, Minneapolis), and IGF1 (gift of
Cliff Rosen, MMCRI). In several experiments, Swiss 3T3 cell
populations were treated with various inhibitors throughout the
36 h of primary FGF1 stimulation. Among these compounds were
histone deacetylase inhibitor trichostatin A (TSA) (Sigma), DNA
replication inhibitors thymidine in high concentration and aphidi-
colin (Sigma), DNA methylation inhibitor azacytidine (Sigma), G9a
histone methylase inhibitor BIX01294 (Sigma), JNK inhibitor II
(Calbiochem, San Diego, CA), p38 MAPK inhibitor SB202190
(Selleckchem, Boston, MA), MEK inhibitor U0126 (Selleckchem),
NFkB inhibitors celastrol (Cayman Chemical, Ann Arbor, MI) and
BMS‐345541 (Sigma), and FGFR inhibitor, PD1666866 (a generous
gift from R.L. Panek, Pfizer). In the experiment with the protein
synthesis inhibitor cycloheximide (Sigma), the primary FGF stimula-
tion period was decreased to 18 h to prevent cell death. Upon
induction of quiescence as well as withdrawal of growth factors, the
cells were washed twice with DMEM media containing 5 units/ml
heparin.
DNA SYNTHESIS STUDY
Throughout the final 36 h of each stimulation condition, the cells
were exposed to 10mg/ml bromodeoxyuridine (Sigma). Once
stimulation schedules were completed, the cells were fixed for a
minimum of 10min in 100% ethanol, washedwith PBS, and DNAwas
denatured by incubation in 1N HCl at 55°C for 30min. The residual
acid was then washed with PBS. Non‐specific binding of antibodies
was prevented by a 30min pre‐exposure to blocking buffer (5%
bovine albumin, 0.1% Triton X‐100, 0.1% sodium azide in PBS),
followed by an 1 h incubation in a 1:200 dilution of monoclonal
mouse anti‐bromodeoxyuridine antibody (Dako, Carpinteria, CA) in
blocking buffer. The cells were then washed with PBS and incubated
for 30min in 1:100 dilution of FITC‐conjugated anti‐mouse IgG
antibodies (Vector, Burlingame, CA). Counting of BrdU‐positive
nuclei in Swiss 3T3 populations was performed using an Olympus
IX70 microscope with a combination of fluorescence and phase
contrast. Two coverslips were studied per each experimental point.
For each coverslip, 500 nuclei were counted; the number of
fluorescent nuclei was recorded to acquire BrdU incorporation
percentages. LEII cells, which have low refraction, were imaged using
an Olympus camera and associated CellSens Standard software
attached to the fluorescent microscope. The cell counter plugin for
Image J software (NIH) was used for counting BrdU‐positive nuclei in
LEII populations. Percentage of BrdU labeled cells with 95%
confidence interval were calculated for each condition. Each
experiment was repeated at least three times.
CELL MIGRATION ASSAY
Linear scratches in cell monolayers were made using a 1,000ml
pipette tip. Photographs of scratches were taken at 0, 24, and 32 h
after monolayer wounding. Per each experimental condition, three
independent wells were studied and in each of them fifteen
microscopic fields were photographed using the 10 objective. The
mean distances covered by the migrating fronts of monolayers and
corresponding SEM were calculated.
CONFOCAL FLUORESCENCE MICROSCOPY
The effects of primary and secondary FGF stimulation on the actin
skeleton of Swiss 3T3 cells and on the intracellular localization of
NFkB were studied using confocal fluorescence microscopy. The cells
were fixed with 4% neutral formalin, pre‐incubated in blocking
permeabilizing buffer (PBS with 5% BSA and 0.1% Triton X100), and
then stained with Oregon green‐conjugated phalloidin and TOPRO3
(both from Invitrogen, Carlsbad, CA). To study the nuclear
translocation of NFkB, fixed and permeabilized cells were first
incubated with rabbit anti‐NFkB antibodies (Abcam, Cambridge, MA)
and then stained with Alexa 488‐conjugated anti‐rabbit IgG
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antibodies (Invitrogen) and TOPRO3. Cell images were taken using
Leica SP1 confocal microscope at the MMCRI confocal microscopy
facility.
IMMUNOBLOT ANALYSIS
Lysates were prepared from Swiss 3T3 monolayers that had
undergone the four basic FGF1 stimulation conditions described
above, after 18 h of the final FGF stimulation The cells were washed
and scraped in ice‐chilled PBS and centrifuged for collection at
2,500 rpm for 10min. NPB buffer (20mM Tris, 250mM sucrose, KCl
60mM, 20mMEDTA, 1.5MNaCl, 1% TritonX‐100, 0.1% deoxycholic
acid, and a 1:10 dilution of protease inhibitor cocktail from Sigma)
was used to lyse the cells. Relative protein concentrations were
determined with Coomassie Plus Protein Assay Kit (Pierce, Rockford,
IL) using a DU 640 spectrophotometer (Beckman, Fullerton, CA) at an
excitation wavelength of 595 nm. The lysate was then mixed with an
equal volume of SDS–PAGE sample buffer and incubated at 95°C for
10min. Equivalent sample amounts were resolved in the l2% PAGE
and transferred to membranes Hybond‐P (GE Healthcare, Little
Chalfont, UK). The membranes were blocked in 5% fat‐free dry milk
diluted in TBS‐Tween buffer at 42°C for 2 h and then blotted with the
appropriate primary mouse or rabbit antibody overnight at 4°C.
Membranes blotted with mouse anti‐GAPDH antibodies (Sigma)
served as loading controls. Antibodies against the following proteins
were used: rabbit antibodies against phosphorylated Erk1/2 (Sigma)
and cyclin D1 (Santa Cruz Biotechnologies, Santa Cruz, CA), mouse
monoclonal antibodies against p21 and p27 (both from BD
Biosciences, San Jose, CA) and cyclin A (Millipore, Temecula, CA).
The bound primary antibodies were visualized using horseradish
peroxidase‐conjugated goat antibodies against rabbit or mouse IgG
(BioRad, Hercules, CA) and the ECL detection system (Amersham,
Piscataway, NJ).
HETEROKARYON ANALYSIS OF CELL PROLIFERATION BLOCKAGE
Fusion of FGF‐primed and “naïve” Swiss 3T3 cells was used to
analyze FGF memory maintenance. FGF priming was achieved by
incubating confluent cultures of Swiss 3T3 cells for 48 h in quiescence
medium, treating them with FGF1 during the following 36 h and then
returning to quiescence for 48 h. Partner naïve Swiss 3T3 cells were
first incubated for 72 h in full culture medium with 0.6mg/ml BrdU,
which resulted in the labeling of 100% nuclei. After that, cells were
transferred to quiescence medium for 48 h. Quiescent FGF‐primed
and naïve cells were dislodged by trypsin, resuspended in full
culture medium, centrifuged, resuspended in cold PBS, counted,
mixed 1:1 and then fused using the HVJ Envelope Cell Fusion Kit
GenomOne‐CFTM (Cosmo Bio Co., Ltd., Tokyo, Japan) according to the
manufacturer protocol. Fused cell were suspended in full cell culture
medium and plated on fibronectin‐coated glass coverslips. One hour
later, they were transferred to quiescence medium and incubated for
48 h. After that, the cells were transferred to fresh quiescence medium
with 10 ng/ml FGF1 and 5mg/ml EdU, incubated for 36 h, fixed with
4% neutral formaldehyde, treated for 20min at room temperature by
4M HCl, washed in PBS and then stained for BrdU as described in the
DNA Synthesis Study section except that fluorescence staining was
achieved using Alexa 546‐conjugated anti‐mouse IgG antibodies
(Invitrogen). Then, EdU incorporation was detected using the Click‐iT
EdU Assay kit (Invitrogen). Fluorescence microscopy was used to
identify the following types of fused cells: (1) Naïve naïve
homodikayons (both nuclei red); (2) primed primed homodikaryons
(both nuclei devoid of red fluorescence); and (3) primed naïve
heterodikaryons (one of two nuclei is red). Percentages of EdU labeled
(green fluorescence in the nuclei) fused cells and corresponding 95%
confidence intervals were calculated for 1, 2, and 3.
STAINING FOR SENESCENCE‐ASSOCIATED b‐GLACTOSIDASE
(SA‐b‐GAL) ACTIVITY
Cells were formalin fixed at the end of each standard treatment
scheme, after 36 of the final FGF1 stimulation, and stained for
SA‐b‐gal activity according to [Dimri et al., 1995].
RT‐PCR
RNA was prepared from Swiss 3T3 cells, which had undergone four
standard treatment schedules, after 18 h of the final FGF1 stimula-
tion, using the RNeasy kit (Qiagen, Hilden, Germany). Expression of
HDACs was assessed by RT‐PCR using the SuperScript kit
(Invitrogen). The following pairs of primers were utilized:
. hdac1 sense: 50‐GGA GAT CTA CCG TCC TCA CAA‐30
. hdac1 antisense: 50‐GCC ATC GCC ATG GTG AAT ATC A‐30
. hdac2. sense: 50‐GGA GGA CTA CAT CAT GCC AAG AA‐30
. hdac2. antisense: 50‐GCT AGG CTG GTA CAT CTC CAT CA‐30
. hdac3. sense: 50‐GGC CAT TAG TGA GGA ACT TCC‐30
. hdac3. antisense: 50‐TCC ACA TCA CTT TCC TTG TCG‐30
. hdac4. sense: 50‐GCT CTC CCA GCT CTC CAG CA‐30
. hdac4. antisense: 50‐GTT GTG AGC TGC TGC ACC GT‐30
. hdac5. sense: 50‐GCC ACG GAC TCC TCT GCA TAG C‐30
. hdac5. antisense: 50‐GGA TGA GCA GCT GCT GCT CC‐30
. hdac6. sense: 50‐TCA GGT CTA CTG TGG TCG TT‐30
. hdac6. antisense: 50‐TCT TCA CAT CTA GGA GAG CC‐30
. hdac7. sense: 50‐GTT CAC CAT GGC AAC GGC AC‐30
. hdac7. antisense: 50‐ACT GCC TGG GAA GAA GTT GCC‐30
. hdac8. sense: 50‐ACC GAA TCC AGC AAA TCC TCA‐30
. hdac8. antisense: 50‐ATA AAA TTC TTC CCC CCA ACT TGC‐30
. hdac9. sense: 50‐ACT GGT TCC ACA GCA GCG CAT AC‐30
. hdac9. antisense: 50‐GTT CCT TCA GCA GTA GGT GCT GC‐30
. hdac10. sense: 50‐CTG TGC TAA CAG GAG CTG TGC ACA‐30
. hdac10. antisense: 50‐CAT GCT CAT AGC GGT GCC AAG AGA‐30
b‐actin was used as a loading control.
RESULTS
PROLIFERATIVE RESPONSE OF SWISS 3T3 CELLS TO REPEATED FGF
STIMULATION
Studies conducted by Andreeva et al. [2004] demonstrated a strong
reduction in DNA replication upon continuous stimulation of Swiss
3T3 cells with FGF1. The initial question asked in the present study
was whether cells acquire memory of FGF1 stimulation and respond
with significantly diminished DNA synthesis to the repeated FGF1
application after a period of quiescence. In a standard experiment,
four stimulation schedules were followed (Fig. 1A). One population of
Swiss 3T3 cells was quiescent for the entire 168 h period of the
experiment. Another population underwent 132 h of quiescence
followed by FGF1 stimulation for the final 36 h of the schedule. In the
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third schedule, the cells were made quiescent for 48 h and then
stimulated for 36 h with FGF1 followed by quiescence for the
remainder of schedule. The fourth schedule of repeated FGF1
stimulation was as follows: 48 h of quiescence, 36 h primary FGF1
stimulation, 48 h intermediate quiescence, and then 36 h of secondary
FGF1 stimulation. BrdUwas present inmedia for the final 36 h of each
stimulation schedule. Analysis of BrdU incorporation demonstrated a
ten‐fold reduction in DNA synthesis after secondary FGF1
Fig. 1. A: Scheme of the repeated FGF1 stimulation experiment (explanation in the text). B: DNA replication is drastically reduced upon repeated stimulation with FGF1. BrdU
incorporation levels were quantified in four different Swiss 3T3 populations. The stimulation schedules were as in (A). BrdU labeling was performed during the final 36 h of each
stimulation schedule. Percentage of BrdU labeled cells with 95% confidence interval for each condition are shown. Here and in further graphs the experiments were repeated at least
three times and the results of representative experiments are presented. (C) Acute establishment of cell “memory” of initial FGF1 stimulation. Swiss 3T3 cells were used for a
repeated stimulation experiment, which in addition to four standard conditions included the four following schedules: QF(12h)QQ—cells were quiescent for 48 h, stimulated with
FGF1 for 12 h, and then put back into quiescence for the remaining 108 h; QF(12h)QF—cells were quiescent for 48 h, stimulated with FGF1 for 12 h, then intermediate quiescence of
72 and 36 h of repeated FGF1 stimulation; QF(5h)QQ—cells were quiescent for 48 h, stimulated with FGF1 for 5 h, and then put back into quiescence for the remaining 115 h;
QF(5h)QF—cells were quiescent for 48 h, stimulated with FGF1 for 5 h, intermediate quiescence of 79 h and then restimulated with FGF1 for 36 h. BrdU labeling occurred
throughout the final 36 h of each stimulation schedule. (D) Cell “memory” of primary FGF1 stimulation is retained throughout an extended intermediate quiescence period.
A repeated FGF1 stimulation experiment was performed with Swiss 3T3 fibroblasts, with an intermediate quiescence period extended from 2 to 5 days. (E) Spontaneous
transformation of Swiss 3T3 cells does not prevent FGF “memory” formation. A standard repeated FGF1 stimulation experiment was performed with spontaneously transformed
Swiss 3T3 cells.
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stimulation, as compared to primary stimulation (Fig. 1B). Next, we
determined how quickly the “memory” of the initial FGF1 stimulation
was established. The primary stimulation period was reduced from 36
to 12 h or 5 h and, as before, BrdU incorporation throughout
secondary stimulation was determined. Both 12 and 5 h primary
stimulations resulted in a significant decrease in DNA replication
upon repeated stimulation with FGF1 (Fig. 1C). It is important to note
that this decrease becomes stronger with extended primary stimula-
tion time. However, even 5 h of primary stimulation was sufficient to
provoke an almost threefold reduction in DNA synthesis upon
secondary FGF1 stimulation; thereby indicating that onset of the
cellular “FGF memory” is acute.
In the following series of experiments, the longevity of the “FGF
memory” was investigated by increasing the intermediate quiescence
period between stimulations from 48 to 120 h. Extension of the
intermediate quiescence period failed to produce a rescue in DNA
replication upon repeated FGF1 stimulation (Fig. 1D), indicating that
the “FGF memory” is stable for at least 120 h.
The maintenance of 3T3 cells at high density for over 10 passages
results in the overgrowth of spontaneously transformed cells, which
have lost the ability to achieve quiescence at low serum concentra-
tion. We produced spontaneously transformed Swiss 3T3 cells and
assessed their response to primary and secondary FGF1 stimulation.
While initial FGF1 treatment failed to increase the ratio of DNA
synthesizing cells, which was already high, secondary stimulation
resulted in a drastic inhibition of DNA replication, to a level well
below the initial “quiescence” (Fig. 1E).
SWISS 3T3 CELLS ARE NOT UNIQUE IN THE “MEMORIZATION” OF
FGF
The establishment of cell “memory” of FGF stimulation has been
firmly proven for spontaneously immortalized Swiss 3T3 mouse
embryo fibroblasts. To assess the extent of this phenomenon,
we performed the FGF restimulation experiments with other
non‐transformed cell cultures: LE II mouse lung endothelial cells
(Fig. 2A), 10T1/2 mouse mesenchymal stem cells (Fig. 2B), mouse
ear‐derived mesenchymal stem cells (Fig. 2C) and human adipose‐
derived stem cells (Fig. 2D). All of these cell types demonstrated a
strong reduction of DNA synthesis in response to repeated FGF1
stimulation, as compared to primary stimulation DNA synthesis
levels.
CELL “MEMORY” AND OTHER GROWTH FACTORS
Because various FGFs, including FGF1 and FGF2, signal through
common receptors, we expected that the phenomenon of cell
“memory” is not unique for FGF1. Indeed, we found that the
restimulation experiments with FGF2 gave the results identical to
those with FGF1. The proliferative response to the secondary FGF2
stimulation after an intermediate 48 h quiescence period was more
than 10‐fold lower than to the primary stimulation (Fig. 3A).
However, unlike FGFs, the experiments with the PDGF‐BB restimu-
lation did not demonstrate the formation of cell “memory” of PDGF
stimulation. Indeed, we did not find a significant difference between
the levels of DNA synthesis induced by the primary and secondary
PDGF‐BB stimulations (Fig. 3B). On the contrary, PDGF‐BB treatment
Fig. 2. “Memorization” of primary FGF1 stimulation in various cells. Standard repeated FGF1 stimulation experiments were performed with Lee II immortalized mouse lung
endothelial cells (A), 10T1/2 mouse mesenchymal stem cells (B), ear‐derived mouse mesenchymal stem cells (C), and adipose‐derived human stem cells (D). Percentage of BrdU
labeled cells with 95% confidence interval for each condition are shown. The experiments were repeated at least three times and the results of representative experiments are
presented.
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Fig. 3. Cells establish “memory” of FGF2 (A) but not of PDGF‐BB (B) stimulation. FGF2 (10 ng/ml) and PDGF‐BB (10 ng/ml) repeated stimulation experiments were carried out on
Swiss 3T3 cells with schedules analogous to those depicted for FGF1 in Figure 1. Percentage of BrdU labeled cells with 95% confidence interval for each condition are shown. Here
and in further graphs the experiments were repeated at least three times and the results of representative experiments are presented. C: Cells previously stimulated with FGF1
respond to PDGF‐BB with a drastically reduced DNA synthesis. A standard repeated FGF1 stimulation experiment was performed with two additional schedules: QP—cells were
quiescent for 132 h followed by 36 h with PDGF‐BB; QFQP—cells were quiescent for 48 h, stimulated with FGF1 for 36 h, followed by 48 h intermediate quiescence, and then PDGF‐
BB stimulation was applied for 36 h. IGF1 (D) and serum (E) rescue DNA synthesis when applied in combination with FGF1 during the secondary but not during the primary
stimulation. D: A standard repeated stimulation experiment was performed including the following additional schedules: QF/IGFQQ—cells were quiescent for 48 h, then stimulated
with FGF1 for 36 h in the presence of 10 ng/ml IGF1 followed by an additional 84 h of quiescence; QF/IGFQF—cells were quiescent for 48 h, then stimulated with FGF1 for 36 h in the
presence of IGF1, followed by 48 h of intermediate quiescence and then FGF1 stimulation was applied for 36 h; QQ/IGF—cells were quiescent for 132 h followed by an additional
36 h in the presence of IGF1 alone; QFQF/IGF—cells were quiescent for 48 h, then stimulated with FGF1 for 36 h, followed by 48 h of intermediate quiescence and then stimulation
with FGF1 was applied for 36 h in the presence of IGF1. E: A standard repeated stimulation experiment was performed containing the following additional schedules: QF/SQQ—cells
were quiescent for 48 h, then stimulated with FGF1 for 36 h in the presence of 10% serum, followed by 84 h of additional quiescence; QF/SQF—cells were quiescent for 48 h, then
stimulated with FGF1 for 36 h in the presence of 10% serum, followed by 48 h of intermediate quiescence and then FGF1 stimulation was applied for 36 h; QFQF/S—cells were
quiescent for 48 h, then stimulated with FGF1 for 36 h, followed by 48 h of intermediate quiescence, and then FGF1 stimulation was repeated for 36 h in the presence of 10% serum.
F: Serum stimulation between the primary and secondary FGF1 treatments does not abolish FGF “memory.” The following experimental schedules were used in this experiment:
QQ—204 h of quiescence; QF—168 h of quiescence followed by 36 h of FGF1 stimulation; QFQQ—48 h of quiescence, 36 h of FGF1 stimulation and 120 h of quiescence; QFSQQ—
48 h of quiescence, 36 h of FGF1 stimulation, 36 h with 10% serum, 84 h of quiescence; QFSQF—48 h of quiescence, 36 h of FGF1 stimulation, 36 h with 10% serum, 48 h of
quiescence, 36 h of FGF1 stimulation.
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of cells, which had been stimulated with FGF1 for 36 h and then
underwent a 48 h period of quiescence, resulted in a dramatic decrease
in DNA synthesis in comparison with FGF‐untreated PDGF‐BB
stimulated cells (Fig. 3C). These data indicate that the loss of
proliferative response to secondary stimulation after FGF treatment is
not due to the loss of FGFRs but to some stable changes that reduce
growth factor‐induced entry to S‐phase.
The observed phenomenon of FGF “memory” could be based on
induced cell senescence. We assessed the activity of senescence‐
associated b‐galactosidase (SA‐b‐gal) in FGF1‐treated Swiss 3T3
cells. While control quiescent cells (132 h quiescence) did not express
SA‐b‐gal, many cells at 36 h after primary or secondary FGF1
stimulation or at 84 h of intermediate quiescence were SA‐b‐gal‐
positive (Supplementary Fig. S2). However, the key characteristic of
senescent cells is their inability to grow in response to proliferation
inducers. To assess the proliferative potential of FGF primed cells, we
applied potent proliferative stimuli. It is well established that the
competence growth factors, including FGFs, cooperate with progres-
sion factors (insulin, IGFs) to support long‐term cell proliferation
[Villaudy et al., 1991]. We found that the combination of FGF1 with
IGF1 during the restimulation of cells that had been previously treated
with FGF1, resulted in a massive induction of DNA replication
(Fig. 3D). In contrast, IGF1 applied alone failed to stimulate DNA
replication in quiescent Swiss 3T3 cells, regardless of prior FGF
stimulation (Fig. 3D). Thus, IGF1 enables cells burdened by the
“memory” of FGF to respond to this mitogen. In contrast, application
of IGF1 with FGF1 during the primary stimulation did not prevent the
formation of FGF “memory,” and the response to the restimulation
with single FGF1 was still drastically reduced (Fig. 3D). Similar to
IGF1, application of 10% bovine calf serum during the initial FGF1
stimulation did not rescue DNA synthesis during the restimulation of
Swiss 3T3 cells with FGF1 alone (Fig. 3E), although the addition of
10% serum during the repeated FGF1 stimulation induced a large
increase in DNA synthesis (Fig. 3E). Thus, although FGF1‐treated cells
exhibited SA‐b‐gal activity, unlike truly senescent cells they were
able to resume proliferation following appropriate stimulations. The
application of 10% serum for 36 h between the primary FGF1
stimulation and 48 h intermediate quiescence failed to rescue the
proliferative response to the subsequent FGF treatment (Fig. 3F). This
observation demonstrates that FGF memory can be retained in
actively growing serum‐stimulated cells.
MORPHOLOGICAL AND SIGNALING RESPONSES IN THE CELLS
RESTIMULATED WITH FGF
One may suggest that the inability of cells to respond with a large
increase of DNA synthesis to the restimulation with FGF is due to
attenuated FGF signaling. Our earlier data that Swiss 3T3 cells
continuously stimulated with FGF, although unable to enter the
second replication cycle, have high levels of Erk1/2 activation
[Andreeva et al., 2004], argue against this suggestion. However, we
have specifically assessed the morphology and signaling events in
cells restimulated with FGF1 after intermediate quiescence. Figure 4A
shows that 84 h after the removal of primary FGF1, cells regained a
typical non‐polarized cobblestone‐like quiescent morphology.
Restimulation with FGF1 resulted in a spindle‐shaped morphology
similar to cells undergoing primary FGF1 stimulation. The confocal
fluorescence study demonstrated that after the secondary FGF1
stimulation, Swiss 3T3 cells formed large sheets of submembrane F
actin, and this response was more pronounced than after primary
FGF1 stimulation (Fig. 4B). Immunoblotting showed that unlike
quiescent cells and similar to cells undergoing primary stimulation,
the restimulated cells had a high content of phosphorylated Erk1/2
(Fig. 4C). In addition, secondary FGF1 stimulation like the primary
treatment induced the production of cyclin D1 (Fig. 4C), which is
similar to cells undergoing a long‐term continuous FGF1 stimulation
[Andreeva et al., 2004]. In contrast, unlike the primary FGF1
treatment, repeated FGF1 stimulation failed to induce the expression
of cyclin A, a critical regulator of cell entry to the S‐phase (Fig. 4D).
Expression of p27, a potent inhibitor of cyclin–CDK complexes
was strongly decreased after both primary and secondary FGF1
stimulation (Fig. 4D). On the contrary, while the expression of p21,
another cyclin–CDK inhibitor, was very low in quiescent cells, it was
dramatically increased after both primary and repeated FGF1
treatment (Fig. 4D). A strong decrease of p21 level in the cells
returned to quiescence after the initial FGF1 stimulation does not
support the hypothesis that this protein might be responsible for the
maintenance of FGF memory. Thus, cells primed with FGF exhibit
most of the responses to FGF stimulation characteristic for naïve cells,
except the expression of cyclin A. Interestingly, in transformed Swiss
3T3 cells, which have lost the ability to quiesce and exhibit a sharp
decrease of DNA synthesis during the intermediated quiescence and
repeated FGF1 stimulation (Fig. 1E), the expression of cyclin A was
decreased already after the primary FGF1 stimulation (Fig. 4E).
FUSION OF FGF PRIMED AND NAÏVE CELLS INHIBITS THE
PROLIFERATIVE RESPONSE TO FGF STIMULATION
Themaintenance of “FGFmemory”may be passive, that is, dependent
exclusively on stable silencing of gene(s) needed for cell entry to the S
phase after FGF restimulation. Alternatively, “FGF memory” may be
supported by an active mechanism, which requires the continuous
persistence of diffusible intracellular proteins preventing the
proliferative response to the secondary FGF stimulation. The active
character of “FGF1memory”maintenance would not exclude a stable
epigenetic reprogramming resulting in the permanent production of
such proteins. Heterokaryon analysis is an established method for
studying the general regulation of cell proliferative status [Zelenin
and Prudovsky, 1989], and we used it to assess whether FGF memory
is maintained through a passive or active mechanism. To distinguish
the nuclei of partner cells in heterokaryons, naïve cells were
prelabeled with a low dose of BrdU and then transferred to
quiescence. The partner cells were primed with FGF1 for 36 h and
then transferred to quiescence medium for 48 h. Naïve and primed
cells were fused with Sendai virus envelopes, plated, transferred for
48 h to the quiescence medium, and then stimulated for 36 h with
FGF1 in the presence of EdU. BrdU labeling was used to distinguish
the nuclei of primed (BrdU negative) and naïve (BrdU positive) cells.
The entry of heterokaryons and control homokaryons to DNA
synthesis was detected by EdU incorporation in their nuclei (Fig. 4F).
As expected, DNA synthesis in primed homodikaryons was five times
lower than in naïve homodikaryons (Fig. 4G). DNA synthesis in
heterodikayons containing one naïve and one primed nucleus was as
low as in primed homodikaryons. These results demonstrate that
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Fig. 4. A: Morphological changes in response to repeated FGF1 stimulation are strongly pronounced. A standard repeated FGF1 stimulation experiment was performed on Swiss
3T3 cells. Combined phase contrast and BrdU immunofluorescence images are presented. Bar: 50mm. (B) Repeated FGF1 stimulation induces an exaggerated restructuring of actin
cytoskeleton. A repeated FGF1 stimulation experiment was performed on Swiss 3T3 cells. Following formalin fixation, cells were co‐stained with FITC‐phalloidin for F‐actin (green)
and TOPRO3 for DNA (blue). Confocal fluorescence images are presented. Bar: 32mm. Phosphorylation of Erk1/2 (C) and expression of Cyclin D1 (C), p21 (D), p27(D), and cyclin
A(D) in response to repeated FGF1 stimulation. Repeated FGF1 stimulation experiments were performed on Swiss 3T3 cells. To assess Erk1/2 phosphorylation, the duration of final
FGF1 stimulation was 45min. Cyclin D1, p21, p27, and Cyclin A expression was determined after 18 h of final FGF1 stimulation. Total cell lysates were resolved by SDS–PAGE and
immunoblotted for phospho‐Erk1/2, Cyclin D1, p21, p27, cyclin A, or GAPDH. E: Expression of cyclin A in transformed Swiss 3T3 cells in response to repeated FGF1 stimulation. F:
Heterokaryon analysis of FGF “memory”maintenance. Quiescent naïve Swiss 3T3 cells prelabeled with BrdU were fused with unlabeled quiescent FGF1 primed cells and stimulated
with FGF1 in presence of EdU as described in “Materials and Methods” section. Confocal immunofluorescence microscopy in combination with phase contrast was used to identify
heterokaryons and study DNA synthesis. BrdU—red. EdU—green. Bar: 16mm. G: In heterokaryons, FGF primed cells suppress the FGF‐induced DNA synthesis in partner naïve nuclei.
Percentages of Edu labeled homo‐ and heterodikaryons with 95% confidence intervals are shown. The experiment was repeated twice with similar results.
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FGF1 memory is maintained in an active manner, apparently due to
the production of diffusible intracellular factors which can prevent
the entry of nuclei to the S phase.
CELLS EXHIBIT ENHANCED MIGRATION AFTER SECONDARY FGF
STIMULATION
Since, unlike DNA synthesis, the morphological response to the
secondary FGF stimulation was unchanged, we next compared the
migratory behavior of Swiss 3T3 cells after the primary and repeated
FGF treatment. Uniform wounds were produced in the monolayers of
Swiss 3T3 cells immediately before the final stimulation with FGF1
and the average distance traveled by the monolayer fronts after 36 h
was determined. Interestingly, the migration of cells after secondary
FGF stimulation was significantly faster than cells in cultures after
primary FGF treatment (Fig. 5). Thus, while FGF pretreatment strongly
reduces the proliferative response to secondary FGF stimulation,
the migratory potential of these cells is not only preserved but
significantly enhanced.
PROTEIN SYNTHESIS, BUT NOT DNA REPLICATION IS REQUIRED FOR
FGF MEMORY FORMATION
Primary stimulation with FGF1 resulted in DNA synthesis. To
determine the contribution of S phase progression to FGF “memory”
formation, repeated stimulation experiments were performed that
included an additional schedule in which DNA synthesis was blocked
throughout the primary stimulation. It was achieved using the
chemical inhibitor aphidicolin or an excess of thymidine, which
halted cell entry to the S‐phase. Both aphidicolin (Fig. 6A) and high
thymidine (Fig. 6B) application during primary stimulation failed to
rescue DNA synthesis in response to repeated FGF1 stimulation.
Conversely, the application of cyloheximide, an inhibitor of protein
synthesis, during the primary FGF stimulation, almost completely
Fig. 5. Repeated FGF stimulation results in enhanced cell migration. A standard repeated FGF1 stimulation experiment was performed. At the end of intermediate quiescence
period, linear scratches in cell monolayers were made as described in Materials and Methods section and then the usual stimulation schedules were followed. One additional
schedule was included: QS—cells monolayers were quiescent for 132 h, then wounded and stimulated with 10% serum. Photograph of scratches were taken at 0, 24, and 32 h after
monolayer wounding (see representative 0 and 32 h photos in A). Mean distances (with corresponding SEM) covered by migrating monolayer fronts by 24 h are presented on B.
P< 0.05. The experiment was repeated three times with similar results.
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Fig. 6. A: Inhibition of DNA synthesis by aphidicolin throughout primary stimulation does not rescue the DNA synthesis following repeated FGF1 stimulation. A standard repeated
FGF1 stimulation experiment was performed with one additional schedule: QF/AQF—cells were quiescent for 48 h, then stimulated with FGF1 for 36 h in the presence of 10mM
aphidicolin, followed by 48 h of intermediate quiescence and then stimulation was repeated for 36 h. Percentage of BrdU labeled cells with 95% confidence interval for each
condition are shown. Here and in further graphs the experiments were repeated at least three times and the results of representative experiments are presented. B: Thymidine block
throughout primary FGF1 stimulation fails to rescue DNA synthesis in response to repeated stimulation. A standard repeated stimulation experiment was performed with one
additional schedule: QF/TQF—cells were quiescent for 48 h, then stimulated with FGF1 for 36 h in the presence of a 2mM thymidine, followed by 48 h of intermediate quiescence
and then repeated FGF1 stimulation for 36 h. C: Protein synthesis inhibition throughout the primary FGF1 stimulation rescues DNA synthesis in response to repeated stimulation. A
standard repeated FGF1 stimulation experiment was modified by decreasing the time of primary FGF1 treatment to 18 h and introducing an additional schedule: QF/CQF—48 h
quiescence, 18 h of FGF1 stimulation in presence of 10mg/ml cycloheximide, 48 h quiescence, 36 h FGF1 stimulation. D: FGF receptor inhibition throughout primary FGF
stimulation rescues DNA synthesis levels in response to repeated FGF stimulation. A standard repeated FGF stimulation experiment was performed with two additional schedules:
QF/FGFRiQQ—cells were quiescent for 48 h, then stimulated with FGF1 in the presence of 1mM FGF receptor inhibitor PD166866 for 36 h, followed by an 84 h of quiescence; QF/
FGFRiQF—cells were quiescent for 48 h, then stimulated with FGF1 in the presence of 1mM PD166866 for 36 h, followed by a 48 h intermediate quiescence and secondary
stimulation with FGF1 for 36 h. E: Inhibition of p38 MAPK and MEK throughout primary FGF1 stimulation rescues DNA synthesis in response to secondary stimulation. A standard
repeated stimulation experiment was performed with the additional schedules: QF/JNKiQF—cells were quiescent for 48 h, then stimulated with FGF1 in the presence of 20mM JNK
inhibitor II, followed by 48 h of intermediate quiescence and finally 36 h of FGF1 stimulation; QF/p38iQF—cells were quiescent for 48 h, then stimulated with FGF1 in the presence
of 10mMof the p38 MAPK inhibitor SB202190, followed by 48 h of intermediate quiescence and finally 36 h of FGF1 stimulation; QF/MEKiQF—cells were quiescent for 48 h, then
stimulated with FGF1 in the presence of 10mM of the MEK inhibitor U0126, followed by 48 h of intermediate quiescence and finally 36 h of FGF1 stimulation.
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rescued the proliferative response to secondary stimulation (Fig. 6C).
Thus, the establishment of cell “memory” of FGF does not require
DNA replication but is dependent on protein synthesis.
FGFR SIGNALING, MAPK ACTIVITY AND NFkB SIGNALING ARE
REQUIRED FOR THE ESTABLISHMENT OF FGF “MEMORY”
The necessity of protein synthesis for formation of “memory” of FGF
stimulation led us to the question of which components of the FGF1
signaling pathway are required for this phenomenon. In the first
series of experiments, we assessed the requirement of FGFR activity. A
repeated stimulation experiment was performed that included all four
standard schedules, as well as two additional schedules in which FGF
receptor signaling was chemically inhibited throughout the primary
FGF1 stimulation period. In one of the additional schedules, the
cells remained in quiescence following primary FGF1 stimulation
and FGFR inhibition; in the other, they underwent repeated FGF1
stimulation following intermediate quiescence. Inhibition of FGFR
throughout primary stimulation with the specific inhibitor PD166866
produced a strong rescue of DNA replication in response to repeated
FGF1 stimulation (Fig. 6D). This result implies that FGFR signaling
directly leads to memory formation; therefore downstream compo-
nents of FGF signaling pathway were considered further.
FGFR signaling activates MAPK p38, ERK1/2, JNK [Maher, 1999;
Makino et al., 2010]. We investigated the contribution of these
kinases to the establishment of cell “memory” of FGF stimulation.
Repeated stimulation experiments containing all standard schedules
and three additional schedules were performed. They included
primary stimulation in the presence of a chemical inhibitor of one of
the investigated kinases followed by intermediate quiescence and
repeated FGF1 stimulation in the absence of kinase inhibitors. We
found that the three kinases unequally contributed to cellular
memory of primary FGF1 stimulation (Fig. 6E). JNK inhibition
throughout the primary stimulation failed to produce a significant
rescue in S phase progression upon repeated FGF1 stimulation.
Inhibition of p38 MAPK throughout the primary stimulation
produced a partial rescue of DNA synthesis in response to secondary
stimulation. An even stronger rescue was associated with the
inhibition of MEK, an upstream kinase of ERK1/2 signaling cascade
(Fig. 6E). Therefore, p38MAPK and to a greater extent ERK1/2 appear
to be involved in the formation of “memory” of FGF1 stimulation.
NFkB signaling, which plays important roles in the regulation of
cell proliferation, is known to be activated by the Ras‐Erk signaling
pathway [Han et al., 2006]. We used NFkB signaling inhibitors to
elucidate whether it is required for the formation of cellular memory
of FGF stimulation. Two inhibitors of NFkB were used: celastrol
(Fig. 7A) and BMS‐345541 (Fig. 7B). For each inhibitor, repeated
stimulation experiments were performed, including an additional
schedule for NFkB inhibition during primary FGF stimulation. Both
inhibitors produced a strong rescue in DNA replication upon
secondary FGF1 stimulation. Activation of the NFkB signaling
results in the translocation of NFkB to cell nuclei [Hatada et al., 2000].
Confocal immunofluorescence study demonstrated that while more
than 99% of quiescent cells had NFkB‐negative nuclei, primary FGF1
stimulation resulted in the presence of NFkB in most cell nuclei
(Fig. 7C). Interestingly the predominant majority of cell nuclei
remained NFkB positive 84 h after the removal of FGF1 and the return
to quiescence medium. Strong nuclear NFkB positivity was
maintained after the secondary FGF stimulation.
HDAC ACTIVITY IS INVOLVED IN THE ESTABLISHMENT OF “FGF1
MEMORY”
The existence of “cell memory” of primary FGF stimulation indicates
that FGF treatment may induce epigenetic changes that prevent the
efficient induction of DNA synthesis in response to secondary
stimulation. These modifications can involve changes in DNA
methylation, histone methylation, and histone acetylation. Swiss
3T3 treatment with the DNA methyltransferase inhibitor azacytidine
throughout the primary FGF stimulation did not prevent the
formation of “FGF memory” (Fig. 8A). Similarly, BIX‐01294,
the inhibitor of histone methyltransferase G9a, which blocks the
dimethylation of histone 3 (H3) lysine 9, failed to block the
establishment of FGF “memory” (Fig. 8B). The involvement of
epigenetic modifiers histone deacetylases (HDAC) in the regulation of
vertebrate development by FGF was reported previously [Xu
et al., 2000]. Therefore, we next assessed the effects of cell treatment
with trichostatin A (TSA), a potent HDAC inhibitor, on “FGF
memory.” As in experiments with azacytidine and BIX‐01296, Swiss
3T3 cells were treated with TSA during primary FGF stimulation
(Fig. 8C). TSA pretreatment resulted in a strong rescue of DNA
synthesis in response to secondary stimulation. This result indicates
that HDAC activity is involved in the formation of cell “memory” of
FGF stimulation. In an attempt to identify the HDAC(s) involved in the
formation of FGF memory, we used RT‐PCR to analyze the effect of
primary and secondary FGF1 stimulation on the expression of
HDAC1‐10. The expression of HDAC 1, 2, 3, 7, and 8 was not
perturbed by FGF stimulation, and the expression of other HDACswas
not detectable (Supplementary Fig. S1). RNAi analysis will be needed
to identify specific HDAC(s) required for the formation of FGF
memory.
DISCUSSION
We found that temporary FGF stimulation resulted in the establish-
ment of cell “memory,”which prevents the efficient induction of DNA
synthesis in response to secondary FGF treatment. The “memory” of
FGF stimulation was retained by immortalized mouse embryo Swiss
3T3 fibroblasts for at least 5 days. The ability to “remember” FGF
stimulation was also exhibited by mesenchymal stem cells, lung
endothelial cells, and adipose‐derived stem cells. Thus, FGF
“memory” is not restricted to Swiss 3T3 cells. Unlike FGF1 and
FGF2, PDGF stimulation did not induce the formation of cell
“memory.” Interestingly, although serum and IGF1 applied simulta-
neously with FGF1 during secondary stimulation rescued DNA
synthesis, their application in the course of primary FGF stimulation
did not prevent the establishment of FGF “memory.” The drastic
decrease of proliferation in transformed Swiss 3T3 cells restimulated
with FGF1 and the preservation of “FGF memory” after an
intermediate period of growth in high serum additionally demon-
strate the resilience of the discovered phenomenon to both cell
transformation and strong proliferative stimulation. While secondary
FGF stimulation failed to efficiently induce DNA synthesis, it resulted
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in high level of Erk1/2 phosphorylation, and, at later time point—
cyclin D1 expression. These results, together with a strongly
decreased proliferative response of cell previously stimulated with
FGF to treatment with PDGF, a growth factor signaling through a
different receptor, indicate that FGF “memory” cannot be explained
by stable internalization or inactivation of FGFR. At the same time,
unlike the primary, secondary FGF stimulation failed to induce the
expression of cyclin A. This deficiency apparently prevents the
efficient transition from the G1 to S phase. Interestingly, “FGF
memory” only limits the proliferative response to the secondary
stimulation, whereas morphological changes and migration are
enhanced.
Inhibitor analysis demonstrated that the establishment of FGF
“memory” depended upon FGFR signaling during primary stimula-
tion. Interestingly, it required the activation of not only MEK‐Erk1/2
pathway but also p38 MAPK. However, the most drastic rescue of
DNA synthesis in response to secondary FGF stimulation was
achieved by inhibition of NFkB signaling during primary FGF
treatment. Rozenblatt‐Rosen et al. [2002] reported that NFkB
signaling activation accompanies the inhibition of chondrocyte
proliferation induced by FGF. It is noteworthy that both Erk1/2 [Kang
et al., 2008] and p38 MAPK [Rajaiya et al., 2008] can activate NFkB
signaling and that activated NFkB can form transcription repressing
complexes with HDAC [Liu et al., 2010]. In accordance with that, TSA,
a potent inhibitor of HDAC, also efficiently rescued the DNA synthesis
in response to repeated FGF stimulation.
These results are corroborated by confocal immunofluorescence
studies, which demonstrated that primary FGF1 stimulation resulted
in translocation of NFkB into the majority of Swiss 3T3 cell nuclei,
which remained NFkB positive for up to 84 h after the removal of
Fig. 7. A: Inhibition of NFkB signaling with celastrol throughout primary stimulation with FGF1 rescues DNA synthesis in response to secondary stimulation. A standard repeated
stimulation experiment was performed with one additional schedule: QF/CQF—cells were quiescent for 48 h, then stimulated with FGF1 for 36 h in the presence of 500 nM celastrol,
made quiescent for another 48 h and then restimulated with FGF1 for 36 h. Percentage of BrdU labeled cells with 95% confidence interval for each condition are shown. Here and in
(B) and (C), the experiments were repeated at least three times and the results of representative experiments are presented. B: Inhibition of NFkB signaling with BMS‐345541
throughout primary FGF1 stimulation rescues DNA synthesis after secondary stimulation. A standard repeated stimulation experiment was performed with one additional schedule:
QF/BMSQF—cells were quiescent for 48 h, then stimulated with FGF1 for 36 h in the presence of 5mM BMS‐345541, made quiescent for another 48 h and then restimulated with
FGF1 for 36 h. C: FGF stimulation results in the persistent nuclear localization of NFkB. A standard repeated stimulation experiment was performed with Swiss 3T3 cells plated on
coverslips. Fixed cells were permeabilized and fluorescently stained for NFkB (green) and DNA (blue). Bar: 32mm.
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FGF1 and return to quiescent conditions. On the other hand,
the heterokaryon analysis demonstrated an active character to
the maintenance of FGF “memory,” which is manifested by the
persistence of unidentified diffusible intracellular factors preventing
the efficient proliferative response to the secondary FGF stimulation.
We suggest that FGFR‐dependent signaling mediated by Erk1/2
and p38 MAPK results in the NFkB‐ and HDAC‐dependent
deacetylation of some regulatory genetic elements, which is
maintained for extended periods and prevents the efficient entry of
cells into the S‐phase upon repeated FGF or PDGF stimulation.
However, this limitation can be superseded if IGF is applied in
the course of the secondary FGF treatment. The genes involved in the
establishment and maintenance of FGF memory remain to be
elucidated.
The existence of FGF “memory” in vivo is yet to be determined.
Some available data indirectly suggests this possibility. The
application of recombinant FGF1 and FGF2 for repair of different
organ and tissue damages has been studied and developed during the
last 20 years [Khurana and Simons, 2003; Barrientos et al., 2008].
However, the results of these studies are still inconclusive in spite of
improvement in the methods of FGF delivery including the use of
polymer implants slowly releasing FGFs [Barrientos et al., 2008].
Indeed, unlike PDGF‐BB, FGFs have not yet been approved by FDA
for clinical use [Barrientos et al., 2008]. Moreover, a recent phase III
clinical study of FGF1 treatment of limb ischemia in diabetic patients
failed to confirm its healing effect. One may suggest that the
inefficiency or low efficiency of recombinant FGFs reported in a
number of studies could be due to the insufficient proliferation caused
by the rapid establishment of FGF “memory.”
Under normal conditions, the availability of endogenous FGFs
in the organism is under strict control at the level of transcription
[Ford‐Perriss et al., 2001]. In addition, unlike most of other members
of FGF family, ubiquitously expressed FGF1 and FGF2 are devoid of
signal peptides and thus are exported through tightly regulated
nonclassical secretion mechanisms [Prudovsky et al., 2008; Nickel
and Rabouille, 2009]. Tissue damage can result in increased FGF
Fig. 8. A: Inhibition of DNAmethylation throughout primary FGF1 stimulation does not interfere with FGF “memory.”A standard repeated stimulation experiment was performed
with one additional schedule: QF/AzaQF—48 h of quiescence, 36 h of FGF1 stimulation in the presence of 5mg/ml Azacytidine, 48 h of intermediate quiescence, and finally 36 h of
repeated FGF1 stimulation. Percentage of BrdU labeled cells with 95% confidence interval for each condition are shown. Here and in further graphs the experiments were repeated
at least three times and the results of representative experiments are presented. B: Inhibition of histone methyltransferase G9a throughout primary FGF1 stimulation does not
interfere with FGF “memory” formation. A standard repeated stimulation experiment was performed with one additional schedule: QF/BIXQF—48 h of quiescence, 36 h of FGF1
stimulation in the presence of 5mMBIX‐01294, 48 h of intermediate quiescence, and finally 36 h of repeated FGF1 stimulation. C: Inhibition of HDAC activity throughout primary
stimulation with FGF1 rescues DNA synthesis in response to secondary stimulation. A standard repeated stimulation experiment was performed with one additional schedule: QF/
TSAQF—48 h of quiescence, 36 h of FGF1 stimulation in the presence of 333 nM TSA, 48 h of intermediate quiescence, and finally 36 h of repeated FGF1 stimulation.
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production and release from local cells and also from invading
macrophages [Zhang et al., 1993; Ganat et al., 2002; Rossini
et al., 2005]. We suggest that “FGF memory” is required for precise
regulation of cell proliferation in the organism, which prevents
excessive cell proliferation and hyperplasia. It is noteworthy that
FGFs are involved in the formation, growth, and metastasis of many
tumors [Korc and Friesel, 2009]. In addition to the loss of cell cycle
control, the enhanced production of IGFs characteristic for various
tumors [Gallagher and LeRoith, 2011] may overcome the FGF
memory and result in continuous proliferation of tumor cells
stimulated by locally produced FGF and IGF. Especially interesting
is the observed “uncoupling” of the proliferation (which is inhibited)
and migration (which is enhanced) in the cells undergoing a
secondary FGF stimulation. One can suggest that while the cells are
expending less energy on DNA synthesis they can devote more of it to
migration. This may also have significance to the in vivo situation.
Indeed FGF release shortly after wounding may stimulate DNA
synthesis, while continuous FGF export could enhance cell migration
needed to fill the wound.
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